Bis(maltolato)oxovanadium(IV)

Research use only, not for human use.

BMOV is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases)inhibitor with insulin-mimicking effects and anti-diabetic properties.

BMOV is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases)inhibitor with insulin-mimicking effects and anti-diabetic properties. BMOV is a potent insulin sensitize. BMOV is shown to improve cardiac dysfunctions in diabetic models. BMOV inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectivelyr.(In Vitro):BMOV treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. BMOV treatment also resultes in an increased glucose uptake in C2C12 cells.(In Vivo):BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.

BMOV; Bis(maltolato)oxovanadium (IV)

Metabolic Enzyme/Protease

Phosphatase

Apoptosis

——

——

38213-69-3

317.2

C12H10O7V

>98% (HPLC)

——

CC(OC=C1)=C([O-]2)C1=O[V+2]23(O=C4C=COC(C)=C4[O-]3)=O

——

(-20℃)

With Ice Pack

≥ 2 years